SG Americas Securities LLC Sells 1,762 Shares of STAAR Surgical (NASDAQ:STAA)

SG Americas Securities LLC cut its stake in STAAR Surgical (NASDAQ:STAA) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,997 shares of the medical instruments supplier’s stock after selling 1,762 shares during the quarter. SG Americas Securities LLC’s holdings in STAAR Surgical were worth $534,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of STAA. JPMorgan Chase & Co. lifted its position in STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after acquiring an additional 172,779 shares during the last quarter. Exome Asset Management LLC bought a new position in shares of STAAR Surgical during the third quarter worth approximately $1,516,000. Franklin Resources Inc. lifted its holdings in STAAR Surgical by 80.1% during the 3rd quarter. Franklin Resources Inc. now owns 31,844 shares of the medical instruments supplier’s stock worth $1,183,000 after purchasing an additional 14,162 shares during the last quarter. Geode Capital Management LLC boosted its stake in STAAR Surgical by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares during the period. Finally, Barclays PLC grew its holdings in STAAR Surgical by 349.4% in the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier’s stock valued at $3,406,000 after buying an additional 71,301 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average price of $21.50 per share, with a total value of $176,751.50. Following the purchase, the insider now directly owns 10,878,007 shares in the company, valued at approximately $233,877,150.50. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders acquired 105,876 shares of company stock valued at $2,487,168. Corporate insiders own 1.00% of the company’s stock.

STAAR Surgical Trading Up 0.9 %

Shares of STAAR Surgical stock opened at $24.19 on Friday. The company has a market cap of $1.19 billion, a PE ratio of 54.98 and a beta of 0.63. The company has a 50 day moving average of $24.68 and a 200-day moving average of $30.48. STAAR Surgical has a 1-year low of $21.13 and a 1-year high of $52.68.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on STAA shares. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. Finally, Stephens raised shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $42.83.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.